Langlara insulin glargine biosimilar: interchangeable Lantus, formulary, and switching

On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy) as an interchangeable biosimilar to Lantus (insulin glargine, Sanofi) for the treatment of adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Langlara is the third interchangeable insulin glargine biosimilar in the US market — and the first biosimilar from a Chinese manufacturer to receive FDA interchangeable designation.

The approval adds a new competitor to an insulin glargine market where biosimilar uptake has been slower than expected despite lower list prices. Sanofi reported approximately $952 million in US Lantus sales in 2025, and industry forecasts suggest a $2–4 billion US glargine biosimilar market by 2028. For health systems, pharmacy directors, and payer teams, Langlara's arrival raises questions about formulary positioning, pharmacy substitution, and whether the competitive dynamics that have held back biosimilar insulin adoption will shift.

This guide maps what access teams, pharmacy buyers, and payer professionals should know about Langlara's coverage, switching, and market context. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

Who this is for

• Pharmacy directors and health-system buyers evaluating formulary positioning
• PBM and payer pharmacy directors assessing biosimilar coverage and substitution policies
• Benefit verification specialists handling insulin claims
• Market access teams at insulin manufacturers tracking competitive dynamics
• Endocrinologists and primary care providers whose patients may be switched to Langlara at the pharmacy counter

Source standard

Every fact in this guide is sourced from the FDA approval notice, the Langlara prescribing information (April 2026), Venable BiologicsHQ analysis, Pharmacy Times coverage, Big Molecule Watch reporting, and the AJMC study on biosimilar insulin glargine uptake. Always verify current formulary status and substitution rules through payer-specific portals and state pharmacy board guidance.

FDA approval and interchangeable designation

The FDA approved Langlara based on a comprehensive analytical, preclinical, and clinical program demonstrating comparable pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity to Lantus in patients with type 1 and type 2 diabetes.

The interchangeability designation means:

• Pharmacy-level substitution: Pharmacists may substitute Langlara for Lantus without prescriber intervention, subject to state pharmacy practice laws
• State notification requirements: Some states require pharmacists to notify the prescriber and/or patient when a substitution occurs; others do not
• No new prescription needed: A current prescription for Lantus can be dispensed as Langlara where state law permits

This is the same interchangeable authority granted to Semglee (insulin glargine-yfgn, approved 2021) and Rezvoglar (insulin glargine-aglr, interchangeable designation approved November 2022).

Insulin glargine biosimilar landscape

Langlara enters a market with established biosimilar competitors:

Biosimilar uptake has been slow

Despite multiple interchangeable biosimilars, uptake of biosimilar insulin glargine has been lower than anticipated. An April 2026 study published in the American Journal of Managed Care found that insulin glargine-yfgn (Semglee) use among older adults remains low despite cost-effectiveness, with barriers including:

• Prescribing inertia: Providers continue prescribing Lantus or Basaglar out of habit
• Formulary placement challenges: Rebate dynamics may make originator Lantus cheaper for PBMs at the net cost level despite higher list prices
• Reimbursement confusion: Pharmacies may not stock biosimilar insulins if reimbursement margins are thinner
• Patient awareness gaps: Patients may not know they can request or be switched to a biosimilar

The AJMC study noted that confidential rebates may reduce net costs for Lantus below those of biosimilars, creating financial disincentives for switching even when list prices are lower.

Formulary and payer coverage

Commercial insurance

Langlara's formulary trajectory will depend on its pricing relative to Semglee, Rezvoglar, and CalRx:

• PBM formularies: The Big Three PBMs (CVS Caremark, Express Scripts, Optum Rx) typically prefer lower-net-cost insulin glargine products. Whether Langlara secures formulary position will depend on its net price (list price minus rebates and fees)
• Step therapy: Some plans may require patients to try a biosimilar insulin glargine before covering Lantus. Langlara would benefit from step-therapy-first policies if it is the preferred biosimilar
• Copay tiers: Biosimilar insulins generally sit on Tier 2 or Tier 3 of commercial formularies with comparable copays to Lantus

Medicare Part D

• $35 monthly insulin cap: Under the Inflation Reduction Act, Medicare Part D beneficiaries pay no more than $35 per month for covered insulin products, including biosimilar insulin glargine
• Formulary requirements: Part D plans must cover at least one insulin glargine product per formulary tier structure
• Langlara positioning: If Langlara is priced below Lantus at the net level, Part D plans may prefer it — but IRA rebate dynamics could change the calculus

Medicaid

• Coverage required: Under the Medicaid Drug Rebate Program, state Medicaid programs must cover FDA-approved insulin products for medically accepted indications
• Supplemental rebate negotiations: States may negotiate additional rebates with Lanexa for Langlara, potentially making it the preferred insulin glargine product

Pharmacy substitution and state law

The interchangeable designation enables pharmacy-level substitution, but the specific rules vary by state:

• Mandatory vs. permissive substitution: Some states require substitution of interchangeable biosimilars; others permit it
• Notification requirements: Most states require the pharmacist to notify the patient of the substitution; some also require prescriber notification within a set timeframe
• Patient refusal: Patients may refuse substitution and request the prescribed brand, though they may face higher cost-sharing
• Electronic prescribing: E-prescribing systems may default to interchangeable biosimilars when a "dispense as written" (DAW) code is not specified

Access teams should verify the specific substitution rules in each state where they operate.

Manufacturer and supply chain

Langlara is manufactured in China, which may raise supply-chain scrutiny from some health systems and payers. The FDA's manufacturing inspection and approval process applies regardless of geography.

Pricing and affordability

Langlara's list price has not been publicly disclosed as of June 2026. Key pricing considerations:

• CalRx benchmark: CalRx insulin glargine pens are available for $55 for a 5-pen pack, setting a new floor for biosimilar insulin pricing
• Semglee pricing: Viatris prices Semglee below Lantus at list price, with an unbranded version priced 65% lower
• IRA impact: The $35 Medicare insulin cap reduces the urgency of switching for Medicare beneficiaries but does not apply to commercial or uninsured patients
• Placeholder estimate: Langlara is expected to price competitively with Semglee and Rezvoglar to gain formulary access

What to monitor

• Launch pricing: Lanexa's list and net pricing strategy for Langlara will determine formulary uptake
• PBM formulary decisions: Watch whether CVS Caremark, Express Scripts, or Optum Rx add Langlara to preferred biosimilar tiers in their 2027 formularies
• Adoption tracking: Whether Langlara achieves faster uptake than Semglee did in its first two years will signal whether the biosimilar insulin market is maturing
• CalRx impact: California's $55 CalRx insulin glargine program may pressure all biosimilar insulin pricing downward
• State substitution laws: Any legislative changes to biosimilar substitution requirements could expand or limit Langlara's reach
• Manufacturing site inspections: Ongoing FDA inspections of the Sunshine Lake Pharma and HEC Pharm facilities in China could affect supply continuity

Sources

• FDA. Langlara (insulin glargine-aldy) Prescribing Information. April 2026. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761412Orig1s000lbl.pdf
• Venable BiologicsHQ. FDA Approves Interchangeable Insulin Glargine Biosimilar Langlara (insulin glargine-aldy). May 7, 2026. Available at: https://biologicshq.com/fda-approves-interchangeable-insulin-glargine-biosimilar-langlara-insulin-glargine-aldy
• Big Molecule Watch. FDA Approves Lannett, Lanexa Biologics, and Sunshine Lake Pharma's Interchangeable Insulin Glargine Biosimilar. May 11, 2026. Available at: https://www.bigmoleculewatch.com/2026/05/11/fda-approves-lannett-lanexa-biologics-and-sunshine-lake-pharmas-interchangeable-insulin-glargine-biosimilar
• Pharmacy Times. FDA Approves New Interchangeable Biosimilar of Insulin Glargine, Expanding Substitution Authority for Pharmacists. May 2026. Available at: https://www.pharmacytimes.com/view/fda-approves-new-interchangeable-biosimilar-of-insulin-glargine-expanding-substitution-authority-for-pharmacists
• Khan SR, Heller DA, Latty LL. Initiation of the Interchangeable Biosimilar Insulin Glargine-yfgn Among Older Adults. Am J Manag Care. 2026;32(4):e126-e132. Available at: https://www.ajmc.com/view/initiation-of-the-interchangeable-biosimilar-insulin-glargine-yfgn-among-older-adults
• CalRx. Biosimilar Insulin Initiative. Available at: https://calrx.ca.gov/biosimilar-insulin-initiative
• Drug Channels. The Big Three PBMs' 2026 Formulary Exclusions. January 2026. Available at: https://www.drugchannels.net/2026/01/the-big-three-pbms-2026-formulary.html